

Appl. No. 10/030,735
Amdt. dated June 24, 2005
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group 1644

PATENT

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A peptide comprising consisting of the sequence R₁-X₁-V-R-X₄-R₂ or partial or full retro-inverso sequences thereof, wherein X₁ is selected from the group consisting of N, Q, D and S; and X₄ is selected from the group consisting of L and F. The X₁-V-R-X₄ sequence is selected from the group consisting of N-V-R-L (SEQ ID NO:57), N-V-R-F (SEQ ID NO: 51), Q-V-R-L (SEQ ID NO: 80), Q-V-R-F (SEQ ID NO:53), and D-V-R-L (SEQ ID NO:102); R₁ is a hydrogen or a peptide of from 1 to 6 amino acids, an acyl or an aryl group; and R₂ is a peptide of from 1 to 3 amino acids, a hydroxide or an amide, provided that the peptide binds α 3 β 1 integrin and does not comprise the sequence FQGVQLQNVRFVF (SEQ ID NO:6) or FRGCVRNLRILSR (SEQ ID NO:12) or DVRF (SEQ ID NO:54).

2. (Currently amended) The peptide of claim 1 containing from about 4 amino acids to about, wherein the peptide contains the X₁-V-R-X₄ sequence and is up to 12 amino acids in length.

3. (Currently amended) The peptide of claim 1 wherein R₁ is a peptide comprising consisting of the sequence selected from the group consisting of FQGVQLQ (SEQ ID NO:13), FAGVQLQ (SEQ ID NO:14), FQGVVAQ (SEQ ID NO:15), FQGVLA (SEQ ID NO:16), and FQGVLN (SEQ ID NO:17).

4. (Currently amended) The peptide of claim 1 A peptide that binds α 3 β 1 integrin, wherein said peptide comprises at least one consists of a sequence selected from the group consisting of FQGVQLQQVRFVF (SEQ ID NO:20), FQGVQLQSVRFVF (SEQ ID NO:21), acQGVLQNVRF (SEQ ID NO:22), FQGVLNQNVRFVF (SEQ ID NO:24), AQGVLQNVRFVF

Appl. No. 10/030,735
Amtd. dated June 24, 2005
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group 1644

PATENT

(SEQ ID NO:25), FAGVLQNVRFVF (SEQ ID NO:26), FQGVAQNVRFVF (SEQ ID NO:27), FQGVLQNVRFVA (SEQ ID NO:28), FQGVLANVRFVF (SEQ ID NO:29), FQGVLQNVRFV (SEQ ID NO:30), QGVLQNVRFVF (SEQ ID NO:31), and FQGVLQNVRF (SEQ ID NO:32).

5. (Currently amended) The peptide of claim 1 wherein $X_1-X_2-X_3-X_4$ the $X_1-V-R-X_4$ sequence is selected from the group consisting of NVRF (SEQ ID NO:51), SVRF (SEQ ID NO:52), and QVRF (SEQ ID NO:53).

6. (Cancel)

7. (Currently amended) The peptide of claim 1 that ~~comprises~~ contains at least one D-amino acid.

8. (Currently amended) A retro-inverso synthetic peptide comprising ~~consisting of the amino acids~~ acid sequence, from C-terminal (left) to N-terminal (right): $r_1-R'_1-X'_1-X'_2-X'_3-X'_4-R'_2$, wherein r_1 denotes a retro-inverso peptide sequence and all amino acids are D amino acids; X'_1 is selected from the group consisting of N, Q, D and S; X'_2 is selected from the group consisting of V, I and L; X'_3 is selected from the group consisting of R and K; and X'_4 is selected from the group consisting of V, I, L and F; the $X'_1-V-R-X'_4$ sequence is selected from the group consisting of N-V-R-L (SEQ ID NO:57), N-V-R-F (SEQ ID NO: 51), Q-V-R-L (SEQ ID NO: 80), Q-V-R-F (SEQ ID NO:53), and D-V-R-L (SEQ ID NO:102); R'_1 is a hydrogen or a peptide of from 1 to 6 amino acids, a hydroxide or an amide; and R'_2 is a peptide of from 1 to 3 amino acids, an acyl or an aryl group.

9. (Currently amended) The peptide of claim 8 containing from about 4 amino acids to about, wherein the peptide contains the $X'_1-V-R-X'_4$ sequence and is up to 12 amino acids in length.

Appl. No. 10/030,735
Amdt. dated June 24, 2005
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group 1644

PATENT

10. (Currently amended) A peptide comprising consisting of the sequence FQGVQLQNVRFVF (SEQ ID NO:6) wherein every amino acid in said sequence is a D-amino acid.

11-12. (Canceled)

13. (Currently amended) A pharmaceutical composition comprising a peptide according to claim 1 and a pharmaceutically acceptable carrier.

14. (Currently amended) A sterile composition comprising a peptide according to claim 1 [[and]] in a sterile aqueous solution.

15-19. (Canceled)

20. (Currently amended) An *in vitro* method of inhibiting adhesion of a cell expressing $\alpha 3\beta 1$ integrin to an extracellular matrix comprising contacting said cell with a peptide according to claim 1.

21. (Original) The method of claim 20 wherein the extracellular matrix comprises TSP1 or laminins.

22. (Cancel)

23. (Original) The method of claim 20 wherein said cell comprises an epithelial or an endothelial cell.

24. (Original) The method of claim 20 wherein said cell is a tumor cell.

Appl. No. 10/030,735
Amdt. dated June 24, 2005
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group 1644

PATENT

25. (Original) The method of claim 20 wherein said cell is a breast carcinoma cell or a small cell lung carcinoma.

26. (Currently amended) An *in vitro* method of inhibiting $\alpha\beta\beta 1$ integrin-mediated cell motility, comprising contacting a cell with a peptide according to claim 1.

27. (Canceled)

28. (Original) The method of claim 26 wherein the cell is an epithelial cell, an endothelial cell or a malignant cell.

29. (Currently amended) An *in vitro* method of inhibiting proliferation of endothelial cells, comprising contacting said cells with a peptide according to claim 1.

30. (Currently amended) An *in vitro* method of inhibiting proliferation of small cell lung carcinoma cells, comprising contacting said cells with a peptide according to claim 2.

31-45. (Canceled)

46. (Currently amended) A peptide comprising consisting of the sequence R₁-D-V-R-F-R₂, or partial or full retro-inverse sequences thereof, wherein D-V-R-F is SEQ ID NO:54; R₁ is a hydrogen or a peptide of from 1 to 6 amino acids, an acyl or an aryl group; and R₂ is a peptide of 2 or 3 amino acids, a hydroxide or an amide, provided that the peptide binds $\alpha\beta\beta 1$ integrin.

47. (Currently amended) The peptide according to claim 46 comprising consisting of the sequence FQGVQLQDVRFVF (SEQ ID NO:19).

Appl. No. 10/030,735
Amdt. dated June 24, 2005
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group 1644

PATENT

48. (New) The peptide of claim 46, wherein the peptide contains the sequence DVRF (SEQ ID NO:54) and is up to 12 amino acids in length.

49. (New) The peptide of claim 46 wherein R₁ is a peptide consisting of the sequence selected from the group consisting of FQGVQLQ (SEQ ID NO:13), FAGVLQ (SEQ ID NO:14), FQGVAQ (SEQ ID NO:15), FQGVLA (SEQ ID NO:16), and FQGVLN (SEQ ID NO:17).

50. (New) The peptide of claim 46 that contains at least one D-amino acid.

51. (New) A composition comprising a peptide according to claim 46 and a pharmaceutically acceptable carrier.

52. (New) A composition comprising a peptide according to claim 46 in a sterile aqueous solution.

53. (New) A retro-inverso synthetic peptide consisting of the amino acid sequence, from C-terminal (left) to N-terminal (right): ri- R'₁-D-V-R-F-R'₂, wherein ri denotes a retro-inverso peptide sequence and all amino acids are D amino acids and D-V-R-F is SEQ ID NO:54; R'₁ is a hydrogen or from 1 to 6 amino acids, a hydroxide or an amide; and R'₂ is 2 or 3 amino acids, a hydroxide or an amide, provided that the peptide binds $\alpha 3\beta 1$ integrin.

54. (New) The peptide of claim 46, wherein the peptide contains the sequence DVRF (SEQ ID NO:54) and is up to 12 amino acids in length.